XML 36 R81.htm IDEA: XBRL DOCUMENT v2.4.1.9
Discontinued Operations The summary of the assets and liabilities related to Pharmaceutical Manufacturing- China discontinued operations (Details) (USD $)
12 Months Ended
Dec. 31, 2014
Dec. 31, 2013
Dec. 31, 2012
Nov. 13, 2012
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Noncontrolling interests $ (441,047)us-gaap_MinorityInterest $ (516,040)us-gaap_MinorityInterest    
Cash and cash equivalents 19,174,061us-gaap_CashAndCashEquivalentsAtCarryingValue 46,133,759us-gaap_CashAndCashEquivalentsAtCarryingValue   12,300,000us-gaap_CashAndCashEquivalentsAtCarryingValue
Total assets     23,800,300us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation  
Loss on exit of segment 0us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax 0us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax (30,267,990)us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax  
Treasury Stock, Shares       104,000us-gaap_TreasuryStockShares
Stock Option Cancelled       117,000nbs_StockOptionCancelled
Warrants Cancelled       64,000nbs_WarrantsCancelled
Pharmaceutical Manufacturing - China business [Member]        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Available-for-sale Securities     13,397,900us-gaap_AvailableForSaleSecurities
/ us-gaap_StatementBusinessSegmentsAxis
= nbs_PharmaceuticalManufacturingChinaBusinessMember
 
Noncontrolling interests     6,015,000us-gaap_MinorityInterest
/ us-gaap_StatementBusinessSegmentsAxis
= nbs_PharmaceuticalManufacturingChinaBusinessMember
 
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax     4,387,400us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
/ us-gaap_StatementBusinessSegmentsAxis
= nbs_PharmaceuticalManufacturingChinaBusinessMember
 
Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents     8,457,500us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents
/ us-gaap_StatementBusinessSegmentsAxis
= nbs_PharmaceuticalManufacturingChinaBusinessMember
 
Restricted cash     2,918,100nbs_DisposalGroupIncludingDiscontinuedOperationRestrictedCash
/ us-gaap_StatementBusinessSegmentsAxis
= nbs_PharmaceuticalManufacturingChinaBusinessMember
 
Accounts receivable, net     6,130,200us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet
/ us-gaap_StatementBusinessSegmentsAxis
= nbs_PharmaceuticalManufacturingChinaBusinessMember
 
Inventory     15,077,700us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory
/ us-gaap_StatementBusinessSegmentsAxis
= nbs_PharmaceuticalManufacturingChinaBusinessMember
 
Prepaid expenses and other current assets     957,800us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets
/ us-gaap_StatementBusinessSegmentsAxis
= nbs_PharmaceuticalManufacturingChinaBusinessMember
 
Property, plant and equipment, net     38,102,000us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNet
/ us-gaap_StatementBusinessSegmentsAxis
= nbs_PharmaceuticalManufacturingChinaBusinessMember
 
Other assets     5,946,300us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets
/ us-gaap_StatementBusinessSegmentsAxis
= nbs_PharmaceuticalManufacturingChinaBusinessMember
 
Total assets     27,216,700us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation
/ us-gaap_StatementBusinessSegmentsAxis
= nbs_PharmaceuticalManufacturingChinaBusinessMember
 
Accounts Payable     (9,604,800)us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable
/ us-gaap_StatementBusinessSegmentsAxis
= nbs_PharmaceuticalManufacturingChinaBusinessMember
 
Accrued liabilities     (2,008,800)us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities
/ us-gaap_StatementBusinessSegmentsAxis
= nbs_PharmaceuticalManufacturingChinaBusinessMember
 
Bank loans     (15,133,500)nbs_DisposalGroupIncludingDiscontinuedOperationBankLoan
/ us-gaap_StatementBusinessSegmentsAxis
= nbs_PharmaceuticalManufacturingChinaBusinessMember
 
Notes payable     (6,599,300)nbs_DisposalGroupIncludingDiscontinuedOperationNotesPayable
/ us-gaap_StatementBusinessSegmentsAxis
= nbs_PharmaceuticalManufacturingChinaBusinessMember
 
Unearned revenue     (9,166,800)us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities
/ us-gaap_StatementBusinessSegmentsAxis
= nbs_PharmaceuticalManufacturingChinaBusinessMember
 
Amount due related parties     (7,859,700)nbs_DisposalGroupIncludingDiscontinuedOperationAmountDueToRelatedParties
/ us-gaap_StatementBusinessSegmentsAxis
= nbs_PharmaceuticalManufacturingChinaBusinessMember
 
Loss on exit of segment   $ (3,416,400)us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
/ us-gaap_StatementBusinessSegmentsAxis
= nbs_PharmaceuticalManufacturingChinaBusinessMember
$ (3,416,400)us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
/ us-gaap_StatementBusinessSegmentsAxis
= nbs_PharmaceuticalManufacturingChinaBusinessMember